Denki Kagaku Kogyo Kabushiki Kaisha

Kao Corporation

Mect Corporation

The Calpis Food Industry Co., Ltd.

Kanto Ishi Pharmaceutical Co., Ltd.

Toshiaki Osawa

Satoshi Toyoshima

Masayoshi Ito

Yoshiyasu Shitori

Haruo Ogura

Masuo Obinata

Kimio Furuhata

Naonobu Yoshizuka

Yoshiyuki Ishii

Yoshio Kobayashi

Masahiro Higuchi

Kazuo Yamamoto

Shoji Yoshimura

Tadashi Hase

Kazutaka Ohmura

Yasunori Nakamura

Eisaku Yoshida

Masaaki Yoshimura

Makoto Asada

Kaoru Nomura

Yoshiro Kobayashi

Yuri Shirakura

Makoto Ujihara

Kazuo Shizume

Lymphotoxin-producing human T-cell hybridomas are incubated in a medium containing phorbol myristate acetate, concanavalin-A or a mixture thereof, the resulting cells are fractionated by sucrose density-gradient centrifugation method to isolate a messenger RNA in 12.6S to 14.6S fractions, and a gene containing a part encoding a polypeptide having a lymphotoxin-activity is prepared from the messenger RNA. The gene is represented by the base sequence of the Table 1 as herein given. Using the present gene, a new lymphotoxin having the amino acid sequence (I) or (II) as given herein can be obtained by genetic engineering technology.

Human lymphotoxin

Lymphotoxin-producing human T-cell hybridomas are incubated in a medium containing phorbol myristate acetate, concanavalin-A or a mixture thereof, the resulting cells are fractionated by sucrose density-gradient centrifugation method to isolate a messenger RNA in 12.6S to 14.6S fractions, and a gene containing a part encoding a polypeptide having a lymphotoxin-activity is prepared from the messenger RNA. The gene is represented by the nucleotide sequence of the Table 1 as herein given. Using the present gene, a new lymphotoxin having the amino acid sequence (I) or (II) as given herein can be obtained by genetic engineering technology.

Method for production of lymphotoxin (TNFB) in cell line A-C5-8

The present invention relates to a monoclonal antibody which specifically binds to a peptide having amino acid sequence (I) described below or having in part at least continuous 4 amino acid sequences of the amino acid sequence (I), and also to a process for producing a monoclonal antibody capable of specifically binding to the peptide represented by the following amino acid sequence:

Monoclonal antibody specific for a human macrophage chemotactic factor

The present invention relates to physiologically active peptides and more particularly, to novel peptides having a specific amino acid sequence which possess a macrophage chemotactic activity.

Novel peptides possessing a macrophage chemotactic activity

The present invention relates to a renal growth promoter based on the finding that luteinizing hormone or an isoform thereof has an effect of promoting renal growth. It was previnsly unknown that luteinizing hormone or an isoform thereof has an effect of promoting renal growth. With the present invention, it is expected that kidneys suffering from a decreased in the number of renal cells or a lowering in the renal function may be activated by administering luteinizing hormone or an isoform thereof.

Renal growth promoter and process for the production of the same

A novel N-acetylneuraminic acid derivative, represented by the general formula: ##STR1## wherein the R.sup.1 groups are, independently, hydrogen or acetyl; R.sup.2 is a nucleoside residue; and R.sup.3 is carboxyl or methoxycarbonyl. The N-acetylneuraminic acid derivative is useful in inhibiting metastasis of cancer cells. Also provided is a process for the preparation of the derivatives.

Sialic acid derivative and process for preparing the same

A process for preparing human T cell hybridomas which are subculturable and produce lymphokines comprising the steps of: (1) treating a human acute leukemia cell with a protein and/or RNA synthesis inhibitor; (2) independently activating a human T cell with a mitogen or antigen; (3) fusing the thus-treated human acute leukemia cell with the thus-activated human T cell in the presence of a fusion accelerator; and (4) isolating the thus-formed hybridoma. An in vivo process for producing lymphokines using the hybridomas is also described.

Process for producing subculturable lymphokine-producing human T cell

Nucleoside or glucose derivatives of N-acetylneuraminic acids are provided, which have immunological activity, are clinically useful, as an immuno suppressive, in particular to treat autoimmune disease such as collagenosis disease without causing any serious side-effects and may be prepared by subjecting a halide of N-acetylneuraminate derivative together with a nucleoside or a glucose to Koenigs-Knorr reaction.

N-Acetylneuraminic acid derivatives and the preparation thereof

Growing community of inventors

Tokyo, Japan

Toshiaki Osawa